Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

24 February 2014

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES FIRST MARKETING AUTHORISATION FOR AIVLOSIN®

IN THE REPUBLIC OF KOREA

ECO is pleased to announce that it has received a marketing authorisation for Aivlosin® 42.5 mg/g premix for swine from the Animal and Plant Quarantine Agency of the Republic of Korea. The product will be marketed for the treatment of swine respiratory disease caused by Mycoplasma hyopneumoniae under ECO’s Valosin^® trade name in this territory.

ECO has a long standing relationship with a South Korean distributor who assisted in obtaining this marketing authorisation. Launch plans are well advanced and is expected to take place within a couple of months.

Pork production is the largest agricultural sector after rice in South Korea, which produces almost one million metric tons of pork every year, with consumption increasing faster than any other type of meat.

Aivlosin^®, ECO’s patented macrolide antibiotic, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

Peter Lawrence, Chairman of ECO, commented “This authorisation in the Republic of Korea is another encouraging and positive step in the development of Aivlosin® as a fast growing, truly global brand. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”

Contacts:

ECO Animal Health Group plc	Â	Marc Loomes	Â	020 8447 8899
Spiro Financial		Anthony Spiro		020 8336 6196
Cenkos Securities plc		Stephen Keys		020 7397 8926

(Nominated Adviser)

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.